Delving into the Latest Updates on CMAB801 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

VEGF-A

Mechanism

VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication

Colorectal Cancer

Originator Organization

Taizhou Mabtech Pharmaceutical Co. Ltd.

Active Organization

Taizhou Mabtech Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the similarity of the pharmacokinetic characteristics of CMAB801 injection and Avastin in Chinese adult male healthy subjects after single administration. Secondary objective: To evaluate the similarity of the safety and immunogenicity of CMAB801 injection and Avastin in Chinese adult male healthy subjects after single administration.

Start Date08 Sep 2021

Sponsor / Collaborator

Taizhou Mabtech Pharmaceutical Co. Ltd.

100 Clinical Results associated with CMAB801

Login to view more data

100 Translational Medicine associated with CMAB801

Login to view more data

100 Patents (Medical) associated with CMAB801

Login to view more data

100 Deals associated with CMAB801

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 1	CN	Taizhou Mabtech Pharmaceutical Co. Ltd.	08 Sep 2021
Colorectal Cancer	Discovery	CN	Taizhou Mabtech Pharmaceutical Co. Ltd.	13 Apr 2018